Abstract
Background: Myoglobin is an oxygen binding protein and its dysfunction has been associated with the pathology of several human disorders. This study was undertaken to investigation the role of hydrogen peroxide (H2O2) in the formation of met-myoglobin and the protective potential of four different reductants such as uric acid, folic acid, glutathione and ascorbic acid were also tested against met-myoglobin formation.
Methods: Human myoglobin was treated with H2O2 in-vitro in order to prepare met-myoglobin. The generation of met-myoglobin was confirmed by UV-visible spectroscopy and its stability was analysed by the treatment of human myoglobin with H2O2 at varying pH or time. High performance liquid chromatography (HPLC) was used to determine the oxidatively modified heme products in met-myoglobin. Spectroscopic analysis was used to identify the protective potential of uric acid, folic acid, glutathione and ascorbic acid against the formation of met-myoglobin. Results: The novel data of this study showed that H2O2 induced extensive damage of myoglobin but the treatment with uric acid, folic acid, glutathione or ascorbic acid provides protection of myoglobin against H2O2 induced oxidative damaged. The study apparently proved the protective potential of all these compounds against the toxicity produced by H2O2. Conclusion: This is the first study that shows uric acid, folic acid, glutathione and ascorbic acid provide protection against the generation of toxic met-myoglobin and might be used therapeutically to modify the blood conditions in order to prevent the progression of human disorders associated with myoglobin dysfunction.Keywords: Met-myoglobin, myoglobin dysfunction, reductants, human disorders, protection, hydrogen peroxide.
Graphical Abstract
[http://dx.doi.org/10.1242/jeb.01172] [PMID: 15339940]
[http://dx.doi.org/10.1038/nrd1307] [PMID: 15043006]
[http://dx.doi.org/10.1016/j.freeradbiomed.2014.05.005] [PMID: 24859377]
[http://dx.doi.org/10.1016/j.jmb.2017.07.004] [PMID: 28697886]
[http://dx.doi.org/10.1002/bmb.20845] [PMID: 25726810]
[PMID: 15548893]
[http://dx.doi.org/10.2174/092986705774463021] [PMID: 16305469]
[http://dx.doi.org/10.1111/1750-3841.14460] [PMID: 30714623]
[PMID: 17987802]
[http://dx.doi.org/10.1080/08916930701574331] [PMID: 17966041]
[http://dx.doi.org/10.1080/10408398.2011.577540] [PMID: 24007423]
[http://dx.doi.org/10.1016/j.lfs.2006.07.041] [PMID: 16945391]
[PMID: 31501645]
[http://dx.doi.org/10.1016/j.clinbiochem.2008.02.013] [PMID: 18359293]
[http://dx.doi.org/10.1016/j.ejphar.2020.173456] [PMID: 32771670]
[http://dx.doi.org/10.3923/ijbc.2008.1.13]
[http://dx.doi.org/10.1179/135100005X57382] [PMID: 16259785]
[http://dx.doi.org/10.1080/08916934.2019.1683545] [PMID: 31656085]
[http://dx.doi.org/10.1016/j.nefro.2017.05.009] [PMID: 28668175]
[http://dx.doi.org/10.1371/journal.pone.0104075] [PMID: 25111140]
[http://dx.doi.org/10.1089/152308601300185250] [PMID: 11396484]
[http://dx.doi.org/10.1097/WOX.0b013e3182439613] [PMID: 23268465]
[http://dx.doi.org/10.1016/j.bbadis.2009.06.005] [PMID: 19545623]
[http://dx.doi.org/10.1021/jf011394w] [PMID: 12083855]
[http://dx.doi.org/10.1016/S0891-5849(99)00223-3] [PMID: 11281297]
[http://dx.doi.org/10.1016/S0891-5849(01)00534-2] [PMID: 11368929]
[http://dx.doi.org/10.1021/acs.analchem.7b01755] [PMID: 28657729]
[http://dx.doi.org/10.1016/S0006-3495(95)80388-7] [PMID: 7612852]
[http://dx.doi.org/10.1016/j.amjmed.2015.04.031] [PMID: 26026842]
[http://dx.doi.org/10.1161/JAHA.114.001138] [PMID: 25559010]
[http://dx.doi.org/10.1080/15257770802138558] [PMID: 18600514]
[http://dx.doi.org/10.1139/apnm-2017-0158] [PMID: 28575637]
[http://dx.doi.org/10.3390/antiox7050062] [PMID: 29702624]
[http://dx.doi.org/10.1016/S0304-4165(01)00235-5] [PMID: 11853951]
[http://dx.doi.org/10.1016/j.freeradbiomed.2007.06.030] [PMID: 18215736]